Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: A cost-effectiveness and cost-utility analysis

Journal of Clinical Oncology

Volumn 26, Issue 6, 2008, Pages 925-933

  Wolowacz, Sorrel E ^a   Cameron, David A ^a   Tate, Helen C ^a   Bagust, Adrian ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; CAF PROTOCOL; GRANULOCYTE COLONY STIMULATING FACTOR; PROTECTIVE AGENT; TAC PROTOCOL; TAXOID; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RELAPSE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DRUG COST; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STOMATITIS; VOMITING; ADJUVANT CHEMOTHERAPY; AXILLA; BREAST TUMOR; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COST BENEFIT ANALYSIS; DECISION TREE; DISEASE FREE SURVIVAL; ECONOMICS; KAPLAN MEIER METHOD; LYMPH NODE; LYMPH NODE METASTASIS; NEUTROPENIA; PATHOLOGY; PROBABILITY; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DECISION TREES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; GREAT BRITAIN; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MARKOV CHAINS; NEOPLASM STAGING; NEUTROPENIA; PROTECTIVE AGENTS; QUALITY-ADJUSTED LIFE YEARS; TAXOIDS;

EID: 39749201899     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.4190     Document Type: Article

References (32)

1. Montero A, Fossella F, Hortobagyi G, et al: Docetaxel for treatment of solid tumours: A systematic review of clinical data. Lancet Oncol 6:229-239, 2005
2. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
3. Roché H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671, 2006
4. Dooley MJ, Singh S, Michael M: Implications of dose rounding of chemotherapy to nearest vial size. Support Care Cancer 12:653-656, 2004
5. Hodgetts A, Raffle A: Prescribing Issues in Breast Cancer, a report on behalf of the Avon Somerset & Wiltshire Cancer Drug Policy Forum. Bristol, United Kingdom, Avon, Somerset and Wiltshire, 2001
6. Martin M, Lluch A, Segui MA, et al: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205-1212, 2006
7. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178-1184, 2005
8. Smith DH, Adams JR, Johnston SRD, et al: A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 13:1590-1597, 2002
9. Twelves C, Boyer M, Findlay M, et al: Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal cancer. Eur J Cancer 37:597-604, 2001
10. Aristides M, Jackson D, Liepa AM, et al: Costs of managing toxicities in non-small cell lung cancer with pemetrexed compared with docetaxel as second-line chemotherapy: Application to the UK setting. Presented at the 6th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, November 9-11, 2003, Barcelona, Spain
11. Ossa D, Briggs A, Cowell W, et al: Utility associated with severity of cancer-related anaemia (CRA): A societal valuation. Presented at the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, October 24-26, 2004, Hamburg, Germany
12. Launois R, Reboul-Marty J, Henry B, et al: A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 10:504-521, 1996
13. Brown R, Hutton J: Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 9:899-907, 1998
14. Weiss R, Woolf S, Demakos E, et al: Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate and fluorouracil-based adjuvant chemotherapy: A study by the Cancer and Leukemia Group B. J Clin Oncol 21:1825-1835, 2003
15. Office for National Statistics 2004: Life expectancy at birth: Methodological options for small populations. http://www.statistics.gov.uk/ methods_quality/publications.asp
16. Kind P: Measuring the value of quality of life in cancer: An index based on EORTC QLQC-30. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL
17. Hillner BE, Smith TJ: Efficacy and cost-effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 324:160-168, 1991
18. National Institute for Health and Clinical Excellence: Guidance on cancer services: Improving outcomes in breast cancer. Manual Update, August 2002. http://www.nice.org.uk/nicemedia/pdf/Breast_cancer_info_public.pdf
19. Scottish Intercollegiate Guidelines Network, Management of Breast Cancer in Women: A draft for the National Meeting, Edinburgh, United Kingdom, 2003
20. Wolowacz S, Roskell N, Christie A, et al: Per-patient cost of hospital care for advanced breast cancer in the UK based on a large patient-level resource utilisation dataset. Value Health 8:A42, 2005 (abstr; PCN29)
21. Brown RE, Hutton J, Burrell A: Cost-effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19:1091-1102, 2001
22. British National Formulary, BNF50, September 2005. http://www.bnf.org/ bnf/bnf/current/ BNF50
23. Curtis L, Netten A: Unit costs of health & social care, 2004. Manchester, United Kingdom, Personal Social Services Research Unit, 2004
24. NICE Guidance No. 107: Trastuzumab for the adjuvant treatment of early stage HER2-positive breast cancer (2006). http://www.nice.org.uk/guidance/index. jsp?action=download&o=33459
25. NICE Guidance No. 112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (2006) http://www.nice.org.uk/ guidance/index.jsp?action=download&o=33642
26. NICE Final Appraisal Determination: Gemcitabine for the treatment of metastatic breast cancer (2006). http://www.nice.org.uk/page.aspx?o=389951
27. IMS Healthcare Oncology Analyzer, MAT, Q2, 2005
28. Italian Multicentre Breast Study with Epirubicin: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. J Clin Oncol 6:976-982, 1988
29. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
30. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
31. Hall P, Walkington J, Douglas S, et al: Quality of life after 5 years tamoxifen for women with early breast cancer. Presented at the British Cancer Research Meeting, July 2-5, 2003, Bournemouth, United Kingdom
32. Poole CJ, Earl HM, Hiller L, et al: Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355:1851-1862, 2006